Literature DB >> 10477084

MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R.

W G North1, M J Fay, J Du.   

Abstract

We have previously provided evidence that an autocrine loop involving vasopressin is present in perhaps all breast cancers. This study now shows MCF-7 breast cancer cells express mRNAs for all currently recognized vasopressin receptor subtypes (V1a, V1b, and V2). Cloning and DNA sequencing over the entire open reading frame of each mRNA revealed that normal sequences representing each receptor were present. However, in addition, an abnormal mRNA for the V2 receptor, expected to give rise to a truncated 'diabetic' protein, was also expressed. Western analysis revealed that all three normal mRNAs gave rise to proteins of sizes compatible with them being functional receptors. The abnormal V2 receptor mRNA also gave rise to proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477084     DOI: 10.1016/s0196-9781(99)00070-4

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

1.  Native MAG-1 antibody almost destroys human breast cancer xenografts.

Authors:  William G North; Roy H L Pang; Guohong Gao; Vincent A Memoli; Bernard F Cole
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

2.  The effect of vasopressin on the Zajdela hepatocellular carcinoma growth rate.

Authors:  I I Khegai; V I Mel'nikova; N A Popova; L A Zakharova; L N Ivanova
Journal:  Dokl Biol Sci       Date:  2014-08-30

3.  Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.

Authors:  Ning Zhao; Stephanie O Peacock; Chen Hao Lo; Laine M Heidman; Meghan A Rice; Cale D Fahrenholtz; Ann M Greene; Fiorella Magani; Valeria A Copello; Maria Julia Martinez; Yushan Zhang; Yehia Daaka; Conor C Lynch; Kerry L Burnstein
Journal:  Sci Transl Med       Date:  2019-06-26       Impact factor: 17.956

4.  Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: constitutive enhancement of calcium signaling in MCF-7 tumor cells.

Authors:  Zhiping Wu; Wayne D Bowen
Journal:  J Biol Chem       Date:  2008-06-06       Impact factor: 5.157

5.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

6.  Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors.

Authors:  Sharla F Young; Cristiana Griffante; Greti Aguilera
Journal:  Cell Mol Neurobiol       Date:  2007-02-21       Impact factor: 4.231

7.  Rapid calcium-dependent activation of Aurora-A kinase.

Authors:  Olga V Plotnikova; Elena N Pugacheva; Roland L Dunbrack; Erica A Golemis
Journal:  Nat Commun       Date:  2010-09-07       Impact factor: 14.919

Review 8.  Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin.

Authors:  D F Alonso; G V Ripoll; J Garona; N B Iannucci; D E Gomez
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

9.  The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.

Authors:  Juan Garona; Marina Pifano; Ulises D Orlando; Maria B Pastrian; Nancy B Iannucci; Hugo H Ortega; Ernesto J Podesta; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Int J Oncol       Date:  2015-04-03       Impact factor: 5.650

10.  A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Authors:  Ruth S Weinberg; Marcelo O Grecco; Gimena S Ferro; Debora J Seigelshifer; Nancy V Perroni; Francisco J Terrier; Analía Sánchez-Luceros; Esteban Maronna; Ricardo Sánchez-Marull; Isabel Frahm; Marcelo D Guthmann; Daniela Di Leo; Eduardo Spitzer; Graciela N Ciccia; Juan Garona; Marina Pifano; Ana V Torbidoni; Daniel E Gomez; Giselle V Ripoll; Roberto E Gomez; Ignacio A Demarco; Daniel F Alonso
Journal:  Springerplus       Date:  2015-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.